CA3025063A1 - Mutants de degradation du proteoglycane pour le traitement du systeme nerveux central - Google Patents

Info

Publication number

CA3025063A1

CA3025063A1 CA3025063A CA3025063A CA3025063A1 CA 3025063 A1 CA3025063 A1 CA 3025063A1 CA 3025063 A CA3025063 A CA 3025063A CA 3025063 A CA3025063 A CA 3025063A CA 3025063 A1 CA3025063 A1 CA 3025063A1

Authority

CA

Canada

Prior art keywords

seq

chondroitinase

composition

polypeptide

deletion

Prior art date

2003-05-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 230000000593 degrading effect Effects 0.000 title description 120
• 238000012217 deletion Methods 0.000 claims abstract description 114
• 230000037430 deletion Effects 0.000 claims abstract description 113
• 239000000203 mixture Substances 0.000 claims abstract description 60
• 210000003169 central nervous system Anatomy 0.000 claims abstract description 32
• 208000014674 injury Diseases 0.000 claims abstract description 26
• 208000027418 Wounds and injury Diseases 0.000 claims abstract description 24
• 230000006378 damage Effects 0.000 claims abstract description 22
• 230000001225 therapeutic effect Effects 0.000 claims abstract description 17
• 238000002360 preparation method Methods 0.000 claims abstract description 4
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 211
• 229920001184 polypeptide Polymers 0.000 claims description 210
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 210
• 150000001413 amino acids Chemical group 0.000 claims description 53
• 101710106625 Chondroitinase-AC Proteins 0.000 claims description 41
• 108010048429 chondroitinase B Proteins 0.000 claims description 30
• -1 continuous infusion Substances 0.000 claims description 29
• 230000008929 regeneration Effects 0.000 claims description 20
• 238000011069 regeneration method Methods 0.000 claims description 20
• 230000014511 neuron projection development Effects 0.000 claims description 17
• 239000003814 drug Substances 0.000 claims description 15
• 238000002347 injection Methods 0.000 claims description 14
• 239000007924 injection Substances 0.000 claims description 14
• 238000013268 sustained release Methods 0.000 claims description 13
• 239000012730 sustained-release form Substances 0.000 claims description 13
• 208000020431 spinal cord injury Diseases 0.000 claims description 12
• 208000034656 Contusions Diseases 0.000 claims description 9
• 150000001875 compounds Chemical class 0.000 claims description 9
• 230000009519 contusion Effects 0.000 claims description 9
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
• 239000003085 diluting agent Substances 0.000 claims description 7
• 206010006074 Brachial plexus injury Diseases 0.000 claims description 6
• 208000030886 Traumatic Brain injury Diseases 0.000 claims description 6
• 201000006417 multiple sclerosis Diseases 0.000 claims description 6
• 230000009529 traumatic brain injury Effects 0.000 claims description 6
• 230000012010 growth Effects 0.000 claims description 5
• 239000007943 implant Substances 0.000 claims description 5
• 238000001802 infusion Methods 0.000 claims description 5
• 230000000699 topical effect Effects 0.000 claims description 5
• 210000005036 nerve Anatomy 0.000 claims description 4
• 108010025020 Nerve Growth Factor Proteins 0.000 claims description 3
• 102000007072 Nerve Growth Factors Human genes 0.000 claims description 3
• 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 claims description 3
• 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims description 3
• 102000014413 Neuregulin Human genes 0.000 claims description 3
• 108050003475 Neuregulin Proteins 0.000 claims description 3
• 108010077641 Nogo Proteins Proteins 0.000 claims description 3
• 102100029831 Reticulon-4 Human genes 0.000 claims description 3
• 239000005557 antagonist Substances 0.000 claims description 3
• 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims description 3
• 239000003102 growth factor Substances 0.000 claims description 3
• 239000003112 inhibitor Substances 0.000 claims description 3
• 230000005764 inhibitory process Effects 0.000 claims description 3
• 239000003900 neurotrophic factor Substances 0.000 claims description 3
• 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 3
• 208000001738 Nervous System Trauma Diseases 0.000 claims 8
• 208000012902 Nervous system disease Diseases 0.000 claims 8
• 208000028412 nervous system injury Diseases 0.000 claims 8
• 238000010255 intramuscular injection Methods 0.000 claims 4
• 239000007927 intramuscular injection Substances 0.000 claims 4
• 238000007913 intrathecal administration Methods 0.000 claims 4
• 238000010253 intravenous injection Methods 0.000 claims 4
• 238000010254 subcutaneous injection Methods 0.000 claims 4
• 239000007929 subcutaneous injection Substances 0.000 claims 4
• 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 abstract description 54
• 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 abstract description 53
• 238000000034 method Methods 0.000 abstract description 16
• 238000009792 diffusion process Methods 0.000 abstract description 14
• 238000011084 recovery Methods 0.000 abstract description 9
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
• 201000010099 disease Diseases 0.000 abstract description 6
• 230000001737 promoting effect Effects 0.000 abstract description 4
• 230000000926 neurological effect Effects 0.000 abstract description 3
• 102000016611 Proteoglycans Human genes 0.000 description 126
• 108010067787 Proteoglycans Proteins 0.000 description 126
• 238000006467 substitution reaction Methods 0.000 description 53
• 230000000694 effects Effects 0.000 description 46
• 150000007523 nucleic acids Chemical class 0.000 description 39
• 108090000623 proteins and genes Proteins 0.000 description 36
• 108020004707 nucleic acids Proteins 0.000 description 33
• 102000039446 nucleic acids Human genes 0.000 description 33
• 102000004190 Enzymes Human genes 0.000 description 32
• 108090000790 Enzymes Proteins 0.000 description 32
• 229940088598 enzyme Drugs 0.000 description 32
• 101000910471 Proteus vulgaris Chondroitin sulfate ABC endolyase Proteins 0.000 description 31
• 210000001519 tissue Anatomy 0.000 description 28
• 102000004169 proteins and genes Human genes 0.000 description 27
• 235000018102 proteins Nutrition 0.000 description 24
• 108090000819 Chondroitin-sulfate-ABC endolyases Proteins 0.000 description 19
• 102000037716 Chondroitin-sulfate-ABC endolyases Human genes 0.000 description 19
• 102100036601 Aggrecan core protein Human genes 0.000 description 18
• 239000000758 substrate Substances 0.000 description 18
• 108010067219 Aggrecans Proteins 0.000 description 17
• 230000014509 gene expression Effects 0.000 description 16
• 210000002241 neurite Anatomy 0.000 description 15
• 210000004027 cell Anatomy 0.000 description 14
• 239000002773 nucleotide Substances 0.000 description 14
• 125000003729 nucleotide group Chemical group 0.000 description 14
• 238000003556 assay Methods 0.000 description 13
• 230000004927 fusion Effects 0.000 description 12
• 230000015556 catabolic process Effects 0.000 description 11
• 238000006731 degradation reaction Methods 0.000 description 11
• 102000037865 fusion proteins Human genes 0.000 description 11
• 108020001507 fusion proteins Proteins 0.000 description 11
• 239000000499 gel Substances 0.000 description 11
• 210000002569 neuron Anatomy 0.000 description 11
• 229920002567 Chondroitin Polymers 0.000 description 10
• DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 10
• 230000006872 improvement Effects 0.000 description 10
• 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 description 9
• 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 description 9
• 210000003050 axon Anatomy 0.000 description 9
• 150000001720 carbohydrates Chemical class 0.000 description 9
• 235000014633 carbohydrates Nutrition 0.000 description 9
• 230000029087 digestion Effects 0.000 description 9
• 230000035515 penetration Effects 0.000 description 8
• 238000001262 western blot Methods 0.000 description 8
• 241000700159 Rattus Species 0.000 description 7
• 230000003197 catalytic effect Effects 0.000 description 7
• 230000006870 function Effects 0.000 description 7
• 238000000338 in vitro Methods 0.000 description 7
• 238000000746 purification Methods 0.000 description 7
• 238000007805 zymography Methods 0.000 description 7
• 101710199046 Chondroitin sulfate ABC exolyase Proteins 0.000 description 6
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
• 239000008186 active pharmaceutical agent Substances 0.000 description 6
• 239000003795 chemical substances by application Substances 0.000 description 6
• 239000013604 expression vector Substances 0.000 description 6
• 230000000670 limiting effect Effects 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 108091028043 Nucleic acid sequence Proteins 0.000 description 5
• 244000110797 Polygonum persicaria Species 0.000 description 5
• 230000028600 axonogenesis Effects 0.000 description 5
• 239000007795 chemical reaction product Substances 0.000 description 5
• 230000002401 inhibitory effect Effects 0.000 description 5
• 239000011159 matrix material Substances 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 239000013598 vector Substances 0.000 description 5
• 229920001287 Chondroitin sulfate Polymers 0.000 description 4
• 102100039283 Hyaluronidase-1 Human genes 0.000 description 4
• 101710199679 Hyaluronidase-1 Proteins 0.000 description 4
• 102100039285 Hyaluronidase-2 Human genes 0.000 description 4
• 101710199674 Hyaluronidase-2 Proteins 0.000 description 4
• 102000015860 Hyaluronidase-3 Human genes 0.000 description 4
• 108050004076 Hyaluronidase-3 Proteins 0.000 description 4
• 102100021081 Hyaluronidase-4 Human genes 0.000 description 4
• 101710199677 Hyaluronidase-4 Proteins 0.000 description 4
• 241000124008 Mammalia Species 0.000 description 4
• 238000002835 absorbance Methods 0.000 description 4
• 238000007792 addition Methods 0.000 description 4
• 230000001580 bacterial effect Effects 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 230000004071 biological effect Effects 0.000 description 4
• 210000004899 c-terminal region Anatomy 0.000 description 4
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
• 238000003776 cleavage reaction Methods 0.000 description 4
• 238000012790 confirmation Methods 0.000 description 4
• 239000013078 crystal Substances 0.000 description 4
• 239000007857 degradation product Substances 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 235000014113 dietary fatty acids Nutrition 0.000 description 4
• 150000002016 disaccharides Chemical class 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 239000000194 fatty acid Substances 0.000 description 4
• 229930195729 fatty acid Natural products 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 239000008194 pharmaceutical composition Substances 0.000 description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
• 239000011541 reaction mixture Substances 0.000 description 4
• 230000007017 scission Effects 0.000 description 4
• 239000003381 stabilizer Substances 0.000 description 4
• 239000004094 surface-active agent Substances 0.000 description 4
• 108020004635 Complementary DNA Proteins 0.000 description 3
• 108020004414 DNA Proteins 0.000 description 3
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• 241000605114 Pedobacter heparinus Species 0.000 description 3
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
• 235000011130 ammonium sulphate Nutrition 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 210000005013 brain tissue Anatomy 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 239000000975 dye Substances 0.000 description 3
• 230000002255 enzymatic effect Effects 0.000 description 3
• 210000002744 extracellular matrix Anatomy 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 238000002825 functional assay Methods 0.000 description 3
• 150000004676 glycans Polymers 0.000 description 3
• 230000005847 immunogenicity Effects 0.000 description 3
• 230000001771 impaired effect Effects 0.000 description 3
• 238000004519 manufacturing process Methods 0.000 description 3
• 230000007659 motor function Effects 0.000 description 3
• 210000000944 nerve tissue Anatomy 0.000 description 3
• 150000004804 polysaccharides Polymers 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 230000037152 sensory function Effects 0.000 description 3
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
• 210000000225 synapse Anatomy 0.000 description 3
• 210000004127 vitreous body Anatomy 0.000 description 3
• SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
• 101710132601 Capsid protein Proteins 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 229920000045 Dermatan sulfate Polymers 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 229920002683 Glycosaminoglycan Polymers 0.000 description 2
• 102000004317 Lyases Human genes 0.000 description 2
• 108090000856 Lyases Proteins 0.000 description 2
• 208000006011 Stroke Diseases 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 230000037424 autonomic function Effects 0.000 description 2
• 230000004888 barrier function Effects 0.000 description 2
• 238000007068 beta-elimination reaction Methods 0.000 description 2
• 238000004166 bioassay Methods 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 239000005018 casein Substances 0.000 description 2
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
• 235000021240 caseins Nutrition 0.000 description 2
• 239000013592 cell lysate Substances 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 229940059329 chondroitin sulfate Drugs 0.000 description 2
• 230000000295 complement effect Effects 0.000 description 2
• 210000003618 cortical neuron Anatomy 0.000 description 2
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
• 210000001787 dendrite Anatomy 0.000 description 2
• AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 2
• 229940051593 dermatan sulfate Drugs 0.000 description 2
• 208000035475 disorder Diseases 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 239000012634 fragment Substances 0.000 description 2
• 239000000017 hydrogel Substances 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 238000002703 mutagenesis Methods 0.000 description 2
• 231100000350 mutagenesis Toxicity 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 230000007903 penetration ability Effects 0.000 description 2
• 230000008521 reorganization Effects 0.000 description 2
• 210000000273 spinal nerve root Anatomy 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 150000004044 tetrasaccharides Chemical class 0.000 description 2
• 230000008733 trauma Effects 0.000 description 2
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
• MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
• 101710192389 Aggrecan core protein Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 108010077805 Bacterial Proteins Proteins 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 206010061431 Glial scar Diseases 0.000 description 1
• 206010018341 Gliosis Diseases 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 108010022901 Heparin Lyase Proteins 0.000 description 1
• 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
• 102000001974 Hyaluronidases Human genes 0.000 description 1
• 108050009363 Hyaluronidases Proteins 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 101100114968 Mus musculus Csf3 gene Proteins 0.000 description 1
• OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
• MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
• 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920001214 Polysorbate 60 Polymers 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 108010076504 Protein Sorting Signals Proteins 0.000 description 1
• 241000588767 Proteus vulgaris Species 0.000 description 1
• 241000700157 Rattus norvegicus Species 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 206010052428 Wound Diseases 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
• 235000001014 amino acid Nutrition 0.000 description 1
• 229940035674 anesthetics Drugs 0.000 description 1
• 238000005571 anion exchange chromatography Methods 0.000 description 1
• 239000003011 anion exchange membrane Substances 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 238000013096 assay test Methods 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
• 239000003833 bile salt Substances 0.000 description 1
• 229940093761 bile salts Drugs 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• MPBRYMWMMKKRGC-UHFFFAOYSA-M carbocyanin DBTC Chemical compound [Br-].C1=CC=CC2=C([N+](=C(C=C(C)C=C3N(C4=C5C=CC=CC5=CC=C4S3)CC)S3)CC)C3=CC=C21 MPBRYMWMMKKRGC-UHFFFAOYSA-M 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 238000005277 cation exchange chromatography Methods 0.000 description 1
• 208000015114 central nervous system disease Diseases 0.000 description 1
• NEUSVAOJNUQRTM-UHFFFAOYSA-N cetylpyridinium Chemical compound CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NEUSVAOJNUQRTM-UHFFFAOYSA-N 0.000 description 1
• 229960004830 cetylpyridinium Drugs 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 229940094517 chondroitin 4-sulfate Drugs 0.000 description 1
• KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
• 229940107200 chondroitin sulfates Drugs 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 239000002872 contrast media Substances 0.000 description 1
• 229940109239 creatinine Drugs 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 239000000287 crude extract Substances 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
• 230000002367 endolytic effect Effects 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• 230000007247 enzymatic mechanism Effects 0.000 description 1
• 238000001952 enzyme assay Methods 0.000 description 1
• SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 239000003193 general anesthetic agent Substances 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 230000002518 glial effect Effects 0.000 description 1
• 229940097043 glucuronic acid Drugs 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 239000003966 growth inhibitor Substances 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 229920002674 hyaluronan Polymers 0.000 description 1
• 229960003160 hyaluronic acid Drugs 0.000 description 1
• 230000036571 hydration Effects 0.000 description 1
• 238000006703 hydration reaction Methods 0.000 description 1
• IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000002093 isoelectric focusing polyacrylamide gel electrophoresis Methods 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
• KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 238000004989 laser desorption mass spectroscopy Methods 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000005374 membrane filtration Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004973 motor coordination Effects 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 230000003988 neural development Effects 0.000 description 1
• 210000005157 neural retina Anatomy 0.000 description 1
• 230000007658 neurological function Effects 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 238000005498 polishing Methods 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 229940048914 protamine Drugs 0.000 description 1
• 229940124272 protein stabilizer Drugs 0.000 description 1
• 210000002804 pyramidal tract Anatomy 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 238000004153 renaturation Methods 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 231100000812 repeated exposure Toxicity 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 239000012047 saturated solution Substances 0.000 description 1
• 230000037390 scarring Effects 0.000 description 1
• 238000007423 screening assay Methods 0.000 description 1
• 230000021317 sensory perception Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 230000036299 sexual function Effects 0.000 description 1
• 238000001542 size-exclusion chromatography Methods 0.000 description 1
• 210000003625 skull Anatomy 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910052938 sodium sulfate Inorganic materials 0.000 description 1
• 235000011152 sodium sulphate Nutrition 0.000 description 1
• 239000000243 solution Substances 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 238000002798 spectrophotometry method Methods 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000005728 strengthening Methods 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 230000008467 tissue growth Effects 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000008736 traumatic injury Effects 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 230000003313 weakening effect Effects 0.000 description 1